Clovis Oncology, Inc. Quarterly Weighted Average Number of Shares Outstanding, Basic from Q1 2020 to Q3 2022

Taxonomy & unit
us-gaap: shares
Description
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
Summary
Clovis Oncology, Inc. quarterly/annual Weighted Average Number of Shares Outstanding, Basic history and growth rate from Q1 2020 to Q3 2022.
  • Clovis Oncology, Inc. Weighted Average Number of Shares Outstanding, Basic for the quarter ending September 30, 2022 was 145M shares, a 19.3% increase year-over-year.
  • Clovis Oncology, Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2021 was 116M shares, a 37% increase from 2020.
  • Clovis Oncology, Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2020 was 84.3M shares, a 56.5% increase from 2019.
Weighted Average Number of Shares Outstanding, Basic, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Basic, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2022 145M +23.4M +19.3% Jul 1, 2022 Sep 30, 2022 10-Q 2022-11-09
Q2 2022 144M +35.6M +32.8% Apr 1, 2022 Jun 30, 2022 10-Q 2022-08-08
Q1 2022 138M +34M +32.6% Jan 1, 2022 Mar 31, 2022 10-Q 2022-05-05
Q4 2021 128M +31.8M +32.9% Oct 1, 2021 Dec 31, 2021 10-K 2022-02-24
Q3 2021 121M +33M +37.3% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 108M +28M +34.8% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
Q1 2021 104M +32.6M +45.5% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 96.7M Oct 1, 2020 Dec 31, 2020 10-K 2022-02-24
Q3 2020 88.3M Jul 1, 2020 Sep 30, 2020 10-K 2022-02-24
Q2 2020 80.5M Apr 1, 2020 Jun 30, 2020 10-K 2022-02-24
Q1 2020 71.7M Jan 1, 2020 Mar 31, 2020 10-K 2022-02-24
* An asterisk sign (*) next to the value indicates that the value is likely invalid.